ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
Trastuzumab deruxtecan shows substantial anti-cancer activity in brain metastases in patients with HER2-positive breast cancer…
Browsing: ESMO
ESMO 2024: Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359),…
ESMO 2024: Long-course radiotherapy is better than short-course for organ preservation in rectal cancer
The COVID-19 pandemic has enabled researchers to show that a long course of radiotherapy given…
ESMO GI: Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering…
ESMO 2023: Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
Patients with metastatic or recurrent cervical cancer not amenable to curative surgery and/or radiotherapy have…
ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours
Detailed results from CABINET (A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo…
ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive mCRPC in the pre-taxane setting
The data from the Phase III PSMAfore trial was presented at the 2023 European Society…
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the…
Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA study were announced showing amivantamab-vmjw in combination with…
ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA-2 study have been announced showing the regimen of…